Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(25%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
4
33%
Ph phase_1
6
50%
Ph phase_4
1
8%

Phase Distribution

6

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(9)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting6
Recruiting3
unknown1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (54.5%)
Phase 24 (36.4%)
Phase 41 (9.1%)

Trials by Status

unknown18%
not_yet_recruiting650%
recruiting325%
completed18%
terminated18%

Recent Activity

3 active trials
Showing 5 of 12
terminatedphase_1

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

NCT05676697
not_yet_recruitingphase_1

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

NCT07209163
not_yet_recruitingphase_1

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07139353
recruitingphase_2

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

NCT06224257
not_yet_recruitingphase_2

Linperlisib in the Treatment of aPRCA

NCT07031115
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05676697Phase 1

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Terminated
NCT07209163Phase 1

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Not Yet Recruiting
NCT07139353Phase 1

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Not Yet Recruiting
NCT06224257Phase 2

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Recruiting
NCT07031115Phase 2

Linperlisib in the Treatment of aPRCA

Not Yet Recruiting
NCT06548347Phase 2

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Not Yet Recruiting
NCT06489808Phase 2

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting
NCT05676710Phase 1

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Completed
NCT06376721Phase 1

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Recruiting
NCT06343935Phase 4

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Not Yet Recruiting
NCT05863871

Real World Study of Linperlisib for Lymphoma Treatment

Not Yet Recruiting
NCT05559008Phase 1

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12